Suitable to use with beer can sizes 330ml, 350ml, 440ml and 500ml, it can be easily worked by using two AA batteries, while a three-year guarantee ensures shoppers are covered for any damages.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Artisan Small Cap Fund stated the following regarding Guidewire Software, Inc. (NYSE:GWRE) in its Q1 2025 investor letter: “Among our top Q1 contributors were Ascendis, Halozyme and Guidewire ...

Artisan Small Cap Fund stated the following regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its Q1 2025 investor letter: “Among our top Q1 contributors were Ascendis, Halozyme ...

Additionally, Ascendis Pharma reported positive outcomes from the ApproaCH Trial, highlighting significant growth improvements in children treated with TransCon CNP. In other developments, Stifel ...

Investing.com -- Shares of Ascendis Pharma A/S (NASDAQ:ASND) climbed 5.8% today after the company announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New ...

Investing.com -- Shares of Ascendis Pharma A/S (NASDAQ:ASND) climbed 5.8% today after the company announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a market capitalization of $9.8 billion, announced today that the U.S. Food and Drug Administration (FDA) has accepted ...

23 Oct 2024 (Johannesburg Stock Exchange) Ascendis Health Limited announced that its application to transfer its listing to the General Segment of the Main Board of the Johannesburg Stock Exchange ...

[2] TransCon refers to "transient conjugation". Ascendis Pharma's innovative technology platform to create new therapies designed to potentially optimise therapeutic effect, including improving ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...